Tag: duocarmycin
Recent Trends of ADCs
Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer therapeutics, offering significant advancements over traditional treatments. The global ADC market is projected to reach $11.29 billion in 2023, with an estimated compound annual growth rate (CAGR) of 9.2% between 2024 and 2030, reflecting substantial economic and scientific interest in this field
A Preclinical Profile of the Potential of BYON3521
A recent article, published in Molecular Cancer Therapeutics, an American Association for Cancer Research (AACR) journal, suggests that BYON3521, a next-generation antibody-drug conjugate being developed by clinical-stage Dutch...
Byondis and Medac Sign Collaboration and Supply Agreements for Trastuzumab Duocarmazine
Dutch clinical stage biopharmaceutical company Byondis has entered into a license, collaboration and supply agreement with Medac, a privately owned pharmaceutical company based in Germany.
Byondis...
Second Generation HER2-antibody-drug conjugate Offers Best-in-Class Potential and Improved Therapeutic Index
In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported...
